Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
ABBV Price Action
Last 7 days
1.2%
Last 30 days
8.7%
Last 90 days
8.1%
Trailing 12 Months
26.9%
ABBV RSI Chart
ABBV Valuation
ABBV Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
ABBV Fundamentals
ABBV Revenue
ABBV Earnings
ABBV Profitability
ABBV Investor Care
ABBV Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 57.4B | 58.3B | 59.6B | 0 |
| 2024 | 54.4B | 55.0B | 55.5B | 56.3B |
| 2023 | 56.7B | 56.0B | 55.1B | 54.3B |
| 2022 | 56.7B | 57.3B | 57.8B | 58.1B |
| 2021 | 50.2B | 53.7B | 55.2B | 56.2B |
| 2020 | 34.1B | 36.2B | 40.6B | 45.8B |
| 2019 | 32.6B | 32.6B | 32.9B | 33.3B |
| 2018 | 29.6B | 30.9B | 32.2B | 32.8B |
| 2017 | 26.2B | 26.7B | 27.3B | 28.2B |
| 2016 | 23.8B | 24.8B | 25.2B | 25.6B |
| 2015 | 20.4B | 21.0B | 21.9B | 22.9B |
| 2014 | 19.0B | 19.3B | 19.6B | 20.0B |
| 2013 | 18.5B | 18.7B | 18.9B | 18.8B |
| 2012 | 17.7B | 17.9B | 18.1B | 18.4B |
| 2011 | 0 | 0 | 0 | 17.4B |
| 2010 | 0 | 0 | 0 | 15.6B |
Get all data in R, Python etc through our Historical Stock Data APIs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| CEO | Mr. Richard A. Gonzalez |
|---|---|
| WEBSITE | abbvie.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 50000 |
